Markets:

Overview

News

Currencies

International

Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.385 +0.245 (+3.99%)

Streaming Delayed Price Updated: 10:50 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday ↗

November 02, 2022

Gainers

Via Benzinga

Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook ↗

November 01, 2022

Via Benzinga

Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation ↗

October 06, 2022

Via Benzinga

Recap: Myriad Genetics Q1 Earnings ↗

May 05, 2022

Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement.

Via Benzinga

Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast ↗

November 01, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 01, 2022

Gainers

Via Benzinga

Dow Drops Over 200 Points; Crude Oil Rises Sharply ↗

November 01, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 01, 2022

On Tuesday, 85 stocks hit new 52-week lows.

Via Benzinga

Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session ↗

November 01, 2022

Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.

Via Benzinga

Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday ↗

November 01, 2022

U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Myriad Genetics: Q3 Earnings Insights ↗

November 01, 2022

Myriad Genetics (NASDAQ:MYGN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM. Here's what investors need to know about the announcement.

Via Benzinga

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

November 01, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Reports Third Quarter Financial Results

November 01, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

October 31, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 1, 2022 ↗

November 01, 2022

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.

Via Benzinga

Earnings Preview: Myriad Genetics ↗

October 31, 2022

Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that Myriad...

Via Benzinga

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

October 26, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform ↗

October 17, 2022

Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.

Via Benzinga

Is Illumina Still the Gamechanger in Genomics Sequencing?

October 04, 2022

Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused

Via MarketBeat

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022 ↗

October 06, 2022

Upgrades

Via Benzinga

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

September 28, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

July 28, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Can Artificial Intelligence Predict Our Future Health? ↗

July 05, 2022

Thousands of financial investors and Wall Street pundits advise people daily about what economic trends are coming, what stocks are hot and what is on the upswing. Those same investors and banks...

Via Benzinga

40 Stocks Moving In Tuesday's Mid-Day Session ↗

May 31, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

Myriad Genetics's Earnings: A Preview ↗

May 04, 2022

Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad...

Via Benzinga

77 Biggest Movers From Yesterday ↗

June 01, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate...

Via Benzinga

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗

April 20, 2022

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...

Via Benzinga

AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer ↗

March 14, 2022

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-...

Via Benzinga

Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

MYGN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.